Camrelizumab and Rivoceranib Improve Upon TACE in Unresectable HCC
Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.
Related Articles
Streamlining Regulatory Requirements to Decentralize Cancer … : Oncology Times
An abstract is unavailable.
ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR
The phase 3 ARES trial of MaaT013 in third-line GI-aGVHD met its primary end point of GI-ORR at day 28.
CRT Plus Chemo Did Not Improve RFS in Resected Gallbladder Cancer
Results from the ACCELERATE trial did not improve relapse-free survival when chemoradiation was added to chemotherapy for patients with resected gallbladder cancer.
Final Program
Join us at #ACT2025 for an opportunity to engage deeply with the latest research, innovative techniques, and collaborative approaches that are shaping our practices. Please…
Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL
Supriya Gupta, MD, details pros/cons with different BTK inhibitors and promising combination therapies in CLL, as well as how liso-cel is affecting care.
SCRT Followed by Cadonilimab/Chemo Shows Responses in pMMR/MSS Rectal Cancer
The NeoCaCRT trial found that SCRT followed by cadonilimab and mFOLFOX6 elicited a pCR of 37.0%, meeting its primary end point for patients with locally…
Some Young Patients With Hodgkin Lymphoma May Be Able to Avoid Transplant
Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.
Predicting Triple-Negative Breast Cancer Immunotherapy… : Oncology Times
An abstract is unavailable.
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma
Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.